Please select the option that best describes you:
Topics:
Hematologic Malignancies • Medical Oncology • CML • Myeloproliferative Neoplasms • Hematology
What is the recommended treatment for Ph+ CML-CP with T315I mutation who did not tolerate dose-reduced ponatinib or asciminib?
Side effects and cytopenias led to treatment discontinuation